Stocks

ChromaDex (NASDAQ:CDXC) Shares Down 8.1% - What's Next?

Published March 7, 2025

ChromaDex Co. (NASDAQ:CDXC) experienced a significant decline in share price, dropping 8.1% during mid-day trading on a Thursday. The stock fell to a low of $7.97 but was last seen at $7.86. During the trading session, about 1,034,433 shares changed hands, which is a notable increase of 25% compared to the average daily volume of 826,390 shares. The previous closing price of the stock was $8.55.

Wall Street Analysts Forecast Growth

Recent evaluations from various analysts provide a somewhat optimistic outlook on ChromaDex. For instance, LADENBURG THALM/SH SH raised its price target for the company from $6.80 to $8.10, while maintaining a "buy" rating in a research note. Additionally, Roth MKM increased its price objective from $6.00 to $8.00 and also issued a "buy" rating on November 6th. In another update, StockNews.com upgraded ChromaDex shares from a "buy" to a "strong-buy" rating in a report earlier this year.

ChromaDex Trading Down 10.1 %

The company's current performance indicators show that it has a 50-day simple moving average of $5.68 and a 200-day simple moving average of $5.13. ChromaDex holds a market capitalization of approximately $587.39 million, a P/E ratio of 767.87, and a beta of 2.21, reflecting its volatility in the market.

Insider Activity at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold a total of 37,161 shares in a transaction on December 13th. These shares were sold at an average price of $6.19, amounting to approximately $230,026. Following this transaction, Jaksch's ownership in ChromaDex has decreased by 13.21%, leaving him with 244,179 shares valued at around $1,511,468. The details of this transaction were filed with the Securities & Exchange Commission, where more information is accessible. Currently, company insiders own about 9.64% of ChromaDex stock.

Institutional Investors Weigh In On ChromaDex

Large-scale investors have also been active in trading ChromaDex shares. D. E. Shaw & Co. Inc. raised its stake dramatically by 1,785.9% in the fourth quarter, now owning 1,011,290 shares valued at $5,365,000 after acquiring an additional 957,665 shares. Arrowstreet Capital Limited Partnership has also increased its holdings by 288.1%, bringing its total to 662,956 shares worth $3,517,000. Additionally, Connor Clark & Lunn Investment Management Ltd. boosted its investment by 189.0% in the same period. Meanwhile, Renaissance Technologies LLC increased its position by 68.0%, now holding 712,788 shares valued at $3,781,000. Institutional investors and hedge funds currently hold about 15.41% of ChromaDex stock.

ChromaDex Company Profile

ChromaDex Corporation focuses on bioscience and the development of products aimed at healthy aging. The company's operations are primarily divided into three segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. It specializes in researching nicotinamide adenine dinucleotide (NAD+) and providing dietary supplement products that feature proprietary ingredients. Moreover, ChromaDex also develops special ingredient technologies and supplies these as raw materials to consumer product manufacturers.

Should You Invest $1,000 in ChromaDex Right Now?

If you are considering ChromaDex, it is essential to evaluate its current standing among financial analysts. Although ChromaDex has a "Buy" rating, leading analysts suggest that there are five stocks that may offer better investment opportunities at this time. Investors should assess these recommendations carefully before making any decisions.

ChromaDex, stocks, analysis